

## **Important notice**

- This document contains statements about Mercia Asset Management PLC that are or may be forward-looking statements. Forward-looking statements include statements relating to (i) future revenues, expenses, earnings, financial condition and future prospects; and (ii) business and management strategies and the expansion and growth of Mercia Asset Management PLC's operations.
- These forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors or advisers of Mercia Asset Management PLC. They involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by such statements. They are based on numerous assumptions regarding the present and future business strategies and the future operating environment. All subsequent oral or written forward-looking statements attributable to Mercia Asset Management PLC or any of its shareholders or any persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. All forward-looking statements included in this document speak only as of the date they were made and are based on information then available to Mercia Asset Management PLC. Investors should not place undue reliance on such forward-looking statements, and Mercia Asset Management PLC does not undertake any obligation to update publicly or revise any forward-looking statements.
- No representation or warranty, expressed or implied, is given regarding the accuracy of the information or opinions contained in this
  document and no liability is accepted by Mercia Asset Management PLC or any of its Directors, members, officers, employees, agents or
  advisers for any such information or opinions.
- This information is being supplied to you for information purposes only and not for any other purpose. This document and the information contained in it does not constitute or form any part of an offer of, or invitation or inducement to apply for, securities.
- The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction.





**Dr Mark Payton**Chief Executive Officer

Co-founder of Mercia, with a PhD in Life Sciences and over 20 years' experience in tech, commercialisation and investing.






KPMG trained chartered accountant and former CFO of Forward Group PLC, with over 20 years' CFO experience of multiple listed and PE-backed technologyled businesses.

Julian Viggars
Chief Investment Officer



Chartered accountant who oversees the Group's equity investment activity, with over 20 years' venture capital experience including Blue Prism IPO.





### Highlights





£1.4bn Group AuM (FY22: c.£959m)



c.£71m Cash realised (FY22: c.£155m)



c.£165m Capital deployed (FY22: c.£124m)



c.£378m Total liquidity (FY22: c.£297m)

#### **Financials**

£25.9m Group revenue

(FY22: £23.2m)

£7.6m Adjusted operating profit (FY22: £8.4m)

£37.8m Unrestricted cash

(FY22: £61.3m)

45.4p NAV/share

(FY22: 45.6p)

O.53p Proposed final dividend Full year dividend of O.86p


(FY22: Full year dividend of 0.80p)

### The model - a debt-free group consistently delivering





- Highly scalable
- Adjacent asset class opportunities
- Recurring predictable fee income
- Growing profitability and operating cash inflow





- Strong focus and discipline
- Invests in emerging funds' portfolio companies, selectively into managed funds and complimentary M&A to scale FuM
- Fully aligned



## The market opportunity


UK domestic impact market segment	Fund management market opportunity	Current national market share
Retail tax efficient SME equity investing  Typically, 1-50 employees, investments of £1m to £10m	£19.5bn (c.£3bn EIS, £5.3bn VCT, £11.2bn BPR)	c.2.5%
Public sector (e.g. British Business Bank) regional debt and venture funds	Existing market of c.£920m	c.22% of existing regional funds
Typically, 1-50 employees, investments of £0.2m to £1m	An additional £1.6bn in next generation funds	
Institutional SME PE  1.4m profitable SMEs, typically less than 50 employees. New to PE deals looking for MBO/succession planning	Limited competition and data availability	North West only (aim is to go national) <5%
Institutional debt and property  Regional SMEs and regeneration property developers, investments are typically £2m to £10m	Limited competition and data availability	West Mids only (aim is to go national) <10%

#### Mercia 20:20

Two years into a three-year strategy


	AuM	PBT	Progressive Dividend
FY22:	£959m	£27.4m	0.80p / share (c.2% yield*)
FY23:	£1.4bn	£2.4m	0.86p / share (c.3% yield*)
FY24:	-	-	-
Progress:	£1.4bn	£29.8m	-
Three-year cumulative target:	c.£1.6bn	c.£60m	-












Total profitable AuM growth in the year of c.£478m (+c.50%); no redemptions

## Long-dated, diversified AuM

- Regional specialist in SME capital provision across the UK, delivered through a physical presence in key regional cities
- Enables strong margins, with blended fee rate of c.2%
- Long-dated funds comprising evergreen or 10-year LP structures – all closed end



## Consolidated statement of comprehensive income

For the year ended 31 March 2023

	Year ended	Year ended
	31 March '23	31 March '22
	£,000	£,000
Revenue	25,881	23,183
Administrative expenses	(21,001)	(17,857)
Realised (loss)/gains on sale of direct investments	(849)	9,878
Fair value movements in direct investments	1,201	11,385
Share-based payments charge	(1,049)	(1,109)
Amortisation of intangible assets	(2,337)	(2,033)
Movement in fair value of deferred consideration	(1,462)	(522)
Operating profit before exceptional item	384	22,925
Exceptional item	(372)	-
Operating profit	12	22,925
Finance income	2,428	4,452
Finance expense	(31)	(15)
Profit before taxation	2,409	27,362
Taxation	427	(1,262)
Profit and total comprehensive income for the year	2,836	26,100
Basic earnings per Ordinary share (pence)	0.64	5.93
Diluted earnings per Ordinary share (pence)	0.63	5.82



• Fair value increase despite sector/economic headwinds

 Professional fees incurred in respect of the acquisition of FDC




### Consolidated statement of financial position

#### As at 31 March 2023

	As at	As a
	31 March '23	31 March '22
	£,000	£,000
Goodwill and intangible assets	39,051	32,355
Property, plant and equipment, and right-of use assets	964	530
Investments	136,550	119,558
Total non-current assets	176,565	152,443
Trade and other receivables	3,787	1,074
Cash and short-term liquidity investments	37,834	61,284
Total current assets	41,621	62,358
Total assets	218,186	214,801
Trade, other payables and lease liabilities	(7,146)	(7,120
Deferred consideration	(1,227)	(2,869
Total current liabilities	(8,373)	(9,989
Lease liabilities	(574)	(295
Deferred consideration	(1,778)	
Deferred taxation	(4,540)	(3,928
Total non-current liabilities	(6,892)	(4,223
Total liabilities	(15,265)	(14,212
Net assets	202,921	200,589
Equity		
Issued share capital	4	4
Share premium	83,744	81,644
Other distributable reserve	63,266	66,919
Retained earnings	51,341	48,505
Share-based payments reserve	4,566	3,517
Total equity	202,921	200,589


- Direct portfolio:
  - Net capital deployed £20.7m
- Significant liquidity with no debt



#### Consolidated statement of cash flows

#### For the year ended 31 March 2023

	Year ended	Year ended
	31 March '23	31 March '22
	£,000	£'000
Net cash generated from operating activities	1,200	9,150
Sale of direct investments	3,744	16,309
Purchase of direct investments	(20,778)	(19,884)
Investee company loan repayments	125	1,500
Investee company loan redemption premiums & interest received	1,979	4,438
Net cash (used in)/generated from direct investment activities	(14,930)	2,363
Interested received from cash deposits	404	14
Purchase of property, plant and equipment	(77)	(76)
Acquisition of FDC	(6,951)	-
Cash acquired with the acquisition of FDC	2,882	-
Purchase of fund management contracts	(2,100)	(2,100)
Decrease/(increase) in short-term liquidity investments	5,000	(5,000)
Net cash used in other investing activities	(842)	(7,163)
Dividends paid	(3,653)	(2,641)
Interest paid	(31)	(15)
Payment of lease liabilities	(238)	(136)
Net cash used in financing activities	(3,922)	(2,792)
Net (decrease)/ increase in cash and cash equivalents	(18,494)	1,558
Cash and cash equivalents at the beginning of the year	56,049	54,491
Cash and cash equivalents at the end of the year	37,555	56,049



 Acquisition of FDC funded from existing liquidity


Continued adoption of a progressive dividend policy



+£0.3m of short-term liquidity investments

#### Mercia share register: 69% free float (2022: 69%)

- Board, management and employees (c.17%)
- Invesco (c.14%)
- Retail (c.10%)
- Ruffer (c.7%)
- BlackRock (c.5%)
- Chelverton Asset Management (c.4%)
- Columbia Threadneedle Investments (c.4%)
- Fidelity (c.4%)
- GPIM (c.3%)
- The Hargreaves No.11 Settlement (c.3%)
- NFU Mutual (c.3%)
- Librae Holdings (c.3%)
- Allianz (c.3%)



#### Others of note:

- Hargreave Hale
- Liontrust
- Ninety One
- West Yorkshire Pension Fund
- Unicorn





### **Assets under Management**

Mercia Ventures Early-stage venture £305m: £0.5m - £5m

National / scale up venture

£325m: £3m - £10m

PE

£48m: £2m - £5m

Regional debt £93m: £0.2m - £1m

National debt

£463m: £1m - £10m



## FY23 - Key investment figures for the Group



#### Group investment

2,639 Investment requests (FY22: 2,604)

c.£165m Capital deployed (FY22: c.£124m)

176 **Business** invested (FY22: 148)

85 New to portfolio (FY22: 95)

Mercia Ventures 1.943 Investment requests

(FY22: c.£84m) (FY22: 2,067)

81 **Business** invested Capital deployed (FY22: 67)

19 New to portfolio (FY22: 43)

Mercia **Private Equity** 

109 Investment requests (FY22: 74)

Capital deployed (FY22: c.£9m)

c.£109m

c.£lm

**Business** invested (FY22: 3)

New to portfolio (FY22: 2)

Mercia Debt

550 Investment requests (FY22: 438)

c.£34m Capital deployed (FY22: c.£13m)

80 Businesses lent to (FY22: 62)

63 New to portfolio (FY22: 48)

Direct Investment

Investment requests (FY22: 25)

c.£21m Capital deployed (FY22: c.£18m)

**Business** invested (FY22: 16)

New to portfolio (FY22: 2)



### Direct investment portfolio - as at 31 March 2023

	Year of first direct investment	Net investment value as at 1 April 2022 £'000	Net cash invested year to 31 March 2023 £'000	Investment realisations year to 31 March 2023 £'000	Realised gains/(loss) year to 31 March 2023 £'000	Fair value movement year to 31 March 2023 £'000	Net investment value as at 31 March 2023 £'000	Equity percentage held as at 31 March 2023 %
nDreams Ltd	2014	25,761	-	-	-	-	25,761	33.2
Impression Technologies Ltd	2015	10,372	4,888	-	-	-	15,260	65.1
Netacea Group Ltd	2022	-	3,000	-	-	8,693	11,693	24.1
Voxpopme Ltd	2018	10,511	625	-	-	(121)	11,015	16.6
Medherant Ltd	2016	8,989	1,709	-	-	236	10,934	38.4
VirtTrade Ltd *	2015	5,387	550	-	-	4,145	10,082	40.6
Warwick Acoustics Ltd	2014	6,306	1,450	-	-	1,939	9,695	40.3
Invincibles Studio Ltd	2015	4,600	626	-	-	3,471	8,697	35.5
Eyoto Group Ltd	2017	2,960	1,514	-	-	1,013	5,487	24.7
Ton UK Ltd **	2015	6,074	-	-	-	(692)	5,382	29.9
Locate Bio Ltd	2018	4,858	-	-	-	-	4,858	18.1
Axis Spine Technologies Ltd	2022	-	3,000	-	-	-	3,000	9.4
sureCore Ltd	2016	2,417	-	-	-	-	2,417	22.0
Nova Pangaea (Holdings) Ltd	2022	-	2,250	-	-	-	2,250	-
Akamis Bio Ltd ***	2015	1,780	-	-	-	-	1,780	1.4
Forensic Analytics Ltd	2021	1,750	-	-	-	-	1,750	8.2
MIP Discovery Ltd	2020	1,449	-	-	-	-	1,449	10.2
Pimberly Ltd	2021	1,375	-	-	-	-	1,375	5.7
MyHealthChecked PLC	2016	1,632	-	-	-	(663)	969	13.1
Uniphy Ltd	2022	-	550	-	-	-	550	-
Other direct investments	n/a	8,926	491	(13)	(2,642)	(4,616)	2,146	n/a
Intechnica Holdings Ltd	2017	14,411	-	(4,000)	1,793	(12,204)	-	-
Total		119,558	20,653	(4,013)	(849)	1,201	136,550	n/a

<sup>\*</sup> Trading as Avid Games

<sup>\*\*</sup> Trading as Intelligent Positioning

<sup>\*\*\*</sup> Formerly PsiOxus Therapeutics Limited, prior to a change in registered name to Akamis Bio Limited in January 2023

## Valuation methodology


- Follow IPEVCV Guidelines
- Over half of the portfolio value based on the price of recent investment round, subsequently calibrated

Listed investment

Enterprise value

Cost

Enterprise value based on most recent trading and market multiples Some use of DCF for calibration Minimal exposure to volatile public market conditions Still adopt a 'hand-on-heart' final review 52,912



# Top 10 holdings, by value (1-5)

	□Dreams	Impression TECHNOLOGIES	NETACEA	Voxpopme*	MEDHERANT
Investment value	£25.8m	£15.3m	£11.7m	£11.0m	£10.9m
% direct holding (excludes FuM)	33.2%	65.1%	24.1%	16.6%	38.4%
Initial year of investment	2014	2015	2022	2018	2016
Description	VR developer	Aluminium pressing	Cyber security	Video analytics	Patch delivery
Board representation	Yes	Yes	Yes	Yes	Yes
Key metrics	Revenue, partnerships, new games	Licences, partnerships	Revenue, ARR	Revenue, ARR	Regulatory, clinical, partnerships
Highlights FY23	Profitable revenue growth	Progress in battery boxes/ recycled aluminium and aerospace	Demerger from Intechnica	Continuing growth, acquisition	3 partners+ internal pipeline development
Valuation change	=	=	•	-	

## Top 10 holdings, by value (6-10)

	EVERYTHING	WARWICK	INVINCIBLES STUDIO	EYOTO	
Investment value	£10.1m	£9.7m	£8.7m	£5.5m	£5.4m
% direct holding (excludes FuM)	40.6%	40.3%	35.5%	24.7%	29.9%
Initial year of investment	2015	2014	2015	2017	2015
Description	Mobile digital trading cards	Flat speaker tech	Mobile soccer management game	Optical solutions	Business intelligence
Board representation	Yes	Yes	Yes	Yes	Yes
Key metrics	Revenue, Partnerships	Licences, partnerships	Revenue, partnerships	Revenue, partnerships	Revenue, ARR
Highlights FY23	Ongoing game revenue growth	Market awareness, OEM deal	Growth, new game development	Regulatory progress	Flat revenues
Valuation change					-

## Direct portfolio value creation

Since IPO in 2014, balance sheet portfolio performance: c.13% IRR

Financial year/investee	Carrying value £'000	Realised value £'000	Premium (%)	
2017				
Abzena plc	150	170	13.3	
Allinea Software Limited	1,900	2,700	42.1	
2018				
Science Warehouse Limited	9,900	10,500	6.1	
2021				
The Native Antigen Company Limited	3,500	5,200	48.6	
Clear Review Limited	1,030	1,040	1.0	
Oxford Genetics Limited	16,100	30,700	90.7	
2022				
Faradion Limited	12,900	19,400	50.4	
2023				
Intechnica Holdings Limited	2,207	4,000	81.2	
Total/average premium	47,687	73,710	54.6	







#### Portfolio size



Mercia Ventures: 258



Mercia Private Equity: 08



Mercia Debt: 301

**Total: 567** 

University spinouts supported: 74

#### Group capital invested


FY21 c.£94m

FY22 c.£124m (↑ c.32%)

FY23 c.£165m (↑ c.33%)

#### Our focus for FY24

- Organic expansion of retail FuM
- Organic expansion of public sector FuM
- Organic expansion of institutional FuM
- Continue progressive dividend
- Drive direct investment performance and cash realisations
- Using own cash resources, continue to evaluate capability and asset growth M&A



### Why invest in Mercia?

Long-term revenue visibility, sustainable profitability and evergreen balance sheet



- 100% of FuM in closed-end funds
- Blended c.2% fee margin
- Well placed for domestic organic FuM expansion
- Diversified direct investment portfolio: c.40% share price discount to NAV
- Strong liquidity:
  - c.£38m, debt-free, balance sheet cash position
  - Additional c.£340m unrestricted FuM cash
- Alignment: employees and Board own 17%
- Resilient direct investment portfolio
- Good progress into FY24 with c.£23m of fund inflows